NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study (Preprint) DOI
Matthieu-P. Schapranow, Mozhgan Bayat, Aadil Rasheed

и другие.

Опубликована: Май 10, 2023

BACKGROUND Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis complex data a wide range daily-life cases. We aim to explore benefits applying AI specific case transplant nephrology: risk prediction severe posttransplant events. For first time, we combine multinational real-world data, which require legal technical protection measures. OBJECTIVE The German-Canadian NephroCAGE consortium aims develop evaluate processes, tools, methods (1) more than 8000 cases over past decades from leading centers Germany Canada, (2) implement measures protect sensitive (3) as foundation developing high-quality prognostic models. METHODS To addressing second objectives, decentralized federated learning infrastructure upon private blockchain. Our enables switch paradigms: instead pooling into central database analysis, it transfer clinical models (CPMs) sites local analyses. Thus, reside protected their original while comparable small are exchanged instead. our third objective, will compare performance selected algorithms, example, random forest extreme gradient boosting, CPMs predict short- long-term risks, graft failure or mortality. be trained on donor recipient retrospective cohorts kidney patients. RESULTS have received initial funding February 2021. All partners applied ethics approval 2022. process exploration variable extraction has started at all In total, 8120 patient records been retrieved August 2023. development validation is ongoing CONCLUSIONS nephrology such basis training privacy-preserving way, system investigate population specifics, understand heterogeneity, treatment specificities, individual impact outcomes. CLINICALTRIAL

INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48892

Язык: Английский

The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors DOI Creative Commons
Kaveh Hadiloo,

Siavash Taremi,

Mahmood Heidari

и другие.

Biomarker Research, Год журнала: 2023, Номер 11(1)

Опубликована: Ноя. 28, 2023

Abstract Today, adoptive cell therapy has many successes in cancer therapy, and this subject is brilliant using chimeric antigen receptor T cells. The CAR with its FDA-approved drugs, could treat several types of hematological malignancies thus be very attractive for treating solid cancer. Unfortunately, the cannot functional cancers due to unique features. This treatment method harmful adverse effects that limit their applications, so novel treatments must use new cells like NK cells, NKT macrophage Among these innate features, are more tumor seem a better candidate prior methods. have vital roles microenvironment and, direct effect, can eliminate efficiently. In addition, being part immune system, attended sites. With high infiltration, modulations effective. review investigates last achievements CAR-macrophage future immunotherapy method.

Язык: Английский

Процитировано

42
Single VHH-directed BCMA CAR-NK cells for multiple myeloma DOI Creative Commons

Quan Ren,

Yingling Zu,

Hongchang Su

и другие.

Experimental Hematology and Oncology, Год журнала: 2023, Номер 12(1)

Опубликована: Ноя. 27, 2023

Язык: Английский

Процитировано

16
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies DOI Creative Commons

Kexin Ai,

Bowen Liu, Xiaomei Chen

и другие.

Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)

Опубликована: Ноя. 5, 2024

Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. However, its application solid tumors is still limited. Clinical studies report suboptimal outcomes such as reduced cytotoxicity of CAR-T cells and tumor evasion, underscoring the need to address challenges sliding cells. Despite improvements from fourth next-generation cells, new include systemic toxicity continuously secreted proteins, low productivity, elevated costs. Recent research targets genetic modifications boost killing potential, metabolic interventions hinder progression, diverse combination strategies enhance therapy. Efforts reduce duration cost developing allogenic in-vivo approaches, promising significant future advancements. Concurrently, innovative technologies platforms potential overcome limitations treating tumors. This review explores optimize therapies for tumors, focusing on enhancing overcoming restrictions. We summarize recent advances T subset selection, structural modifications, infiltration enhancement, interventions, production optimization, integration novel technologies, presenting therapeutic approaches that could improve therapy's applicability

Язык: Английский

Процитировано

7
Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy DOI
Qihang Wu,

Han Mao,

Zhengting Jiang

и другие.

Immunology, Год журнала: 2024, Номер 172(3), С. 343 - 361

Опубликована: Фев. 25, 2024

Abstract Pancreatic cancer (PC) is a highly malignant tumour of the digestive system with poor therapeutic response and low survival rates. Immunotherapy has rapidly developed in recent years achieved significant outcomes numerous neoplasms. However, responses to immunotherapy PC are rare, immunosuppressive desmoplastic microenvironment (TME) significantly hinders their efficacy PC. Tumour‐associated neutrophils (TANs) play crucial role exert profound influence on by establishing robust stromal shelter restraining immune cells assist escape, which may subvert current status immunotherapy. The present review aims offer comprehensive summary latest progress understanding involvement TANs functions emphasise potential implications focusing this deleterious disease. Finally, we provide an outlook for future use

Язык: Английский

Процитировано

6
CRISPR-Cas9 in basic and translational aspects of cancer therapy DOI
Maryam Samareh Salavatipour,

Zahra Poursalehi,

Negin Hosseini Rouzbahani

и другие.

Bioimpacts, Год журнала: 2024, Номер 14(6), С. 30087 - 30087

Опубликована: Март 10, 2024

The discovery of gene editing techniques has opened a new era within the field biology and enabled scientists to manipulate nucleic acid molecules. CRISPR-Cas9 genome engineering revolutionized this achievement by successful targeting DNA molecule its sequence. Since genomic changes are basis birth growth many tumors, method been successfully applied identify genes which involved in initiating driving some neoplastic processes.

Язык: Английский

Процитировано

4
Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer DOI Creative Commons

Lvying Wu,

Lingfeng Zhu, Jin Chen

и другие.

Clinical and Translational Medicine, Год журнала: 2025, Номер 15(4)

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy DOI

Mohadeseh Mohammad Taheri,

Fatemeh Javan,

Mohadeseh Poudineh

и другие.

Clinical Reviews in Allergy & Immunology, Год журнала: 2024, Номер 66(3), С. 328 - 362

Опубликована: Июль 12, 2024

Язык: Английский

Процитировано

3
Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review DOI

Chaozhi Tang,

Yuling Zhang

Pathology - Research and Practice, Год журнала: 2024, Номер 262, С. 155518 - 155518

Опубликована: Авг. 10, 2024

Язык: Английский

Процитировано

3
Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy DOI Creative Commons
Di Chen, Lixia Xu,

Mengjuan Xuan

и другие.

Clinical and Translational Medicine, Год журнала: 2024, Номер 14(9)

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

3
The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases DOI Creative Commons

Jinhui Shu,

Wei Xie,

Zhaozhao Chen

и другие.

Med, Год журнала: 2024, Номер 5(6), С. 495 - 529

Опубликована: Апрель 11, 2024

Chimeric antigen receptor (CAR) T cells have made a groundbreaking advancement in personalized immunotherapy and achieved widespread success hematological malignancies. As CAR technology continues to evolve, numerous studies unveiled its potential far beyond the realm of oncology. This review focuses on current applications CAR-based cellular platforms non-neoplastic indications, such as autoimmune, infectious, fibrotic, senescence-associated diseases. Furthermore, we delve into utilization CARs non-T cell populations natural killer (NK) macrophages, highlighting their therapeutic conditions offering for targeted, therapies improve patient outcomes enhanced quality life.

Язык: Английский

Процитировано

2